Biotech | January 25, 2022
SQI Diagnostics inks pact with UK-Based Owlstone Medical
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Ram’s appointment follows the launch of the CDI India division in October 2021.
Yoga helps to build a strong immune system and daily breathing regime of 10-minute helps in the long run
It provides Covid-19 detection and Omicron surveillance in less than two hours
_256_384.jpg)
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Subscribe To Our Newsletter & Stay Updated
